February 11, 2020

Dermata Therapeutics Announces Completion of Enrollment in a Phase 2b Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris

-Top-line results expected June 2020

SAN DIEGO, Feb. 11, 2020 /PRNewswire/ -- Dermata Therapeutics, LLC, a privately held biotechnology company, announced today that it has completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two groups, DMT310 or placebo, at 14 sites across the United States.

"Today's completion of enrollment marks a significant milestone for Dermata and our DMT310 program as we advance this unique product for the treatment of acne," states Christopher Nardo, PhD., Dermata's SVP, Development. "DMT310 offers a new approach to the treatment of acne with its ONCE WEEKLY application and combination of mechanical and biological mechanisms of actions that is 100% natural. We are very pleased with the positive feedback we have received from both physicians and patients, and we look forward to top line results in June 2020."

DMT310-003 Trial Design:
DMT310-003, is a 12-week, multi-center, double-blind, randomized, placebo controlled trial designed to evaluate the safety, tolerability and efficacy of once weekly dosing of DMT310 in 182 moderate-to-severe acne patients, defined as a grade 3 or 4 on the Investigator Global Assessment (IGA) five-point scale with at least 20 inflammatory and 20 non-inflammatory lesions on the face. The trial contained two arms: (1) DMT310 + H_2O_2; and (2) Placebo + H_2O_2. The primary endpoint is the absolute change from baseline in inflammatory lesion count at week 12. The secondary endpoints are absolute change from baseline in noninflammatory lesion count and the IGA treatment success at week 12, defined as percentage of patients with at a two-point reduction on IGA compared to baseline. The trial also uses a HIPAA compliant smartphone application on patients' mobile devices to document treatment compliance. During the study, patients will record at ten second video, which is then reviewed by clinic staff, to ensure complete and timely application of the product.

About DMT310: DMT310 is a natural product derived from a rare variant of freshwater sponge that is harvested under specific environmental conditions and then processed into a powdered. The powder is mixed with hydrogen peroxide immediately prior to application and only needs to be applied once per week. The product's multiple mechanisms of action can treat the several clinical and aesthetic skin conditions.

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of skin conditions. Dermata has a team of experienced individuals who are currently focused on progressing two programs for the treatment of acne vulgaris and aesthetic indications. To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.

CONTACT: Dermata Contact
Sean Proehl
Investor Relations
858-208-6766
sproehl@dermatarx.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/dermata-therapeutics-announces-completion-of-enrollment-in-a-phase-2b-trial-of-once-weekly-topical-application-of-dmt310-for-the-treatment-of-moderate-to-severe-acne-vulgaris-301002478.html

SOURCE Dermata Therapeutics, LLC